Home » Topics » BioWorld Science, Conferences

BioWorld Science, Conferences
RSS

MODERN study of maraviroc regimen in HIV-1 infection does not meet primary endpoint

July 24, 2014

Researchers present phase II data for ELND-005

July 23, 2014

Celon Pharma describes novel PDE9A inhibitors with procognitive potential

July 23, 2014

Implantation of cells secreting NGF proves safe in Alzheimer's disease study

July 23, 2014

Passive immunization against N-terminally truncated beta-amyloid species with NT4X-167 tested

July 23, 2014

MARCH8 protein blocks HIV-1 infection

July 22, 2014

AbbVie's multidrug regimen for HCV evaluated in patients with HIV co-infection

July 22, 2014

Novel tau aggregation inhibitors for the treatment of tauopathies

July 22, 2014

Novel transgenic model of early Alzheimer's disease induces amyloid cascade

July 21, 2014

Combined acetylcholinesterase inhibitor/calcium channel blocker tested in AD model

July 21, 2014

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 2, 2026.
Small-molecule TREM2 agonist advances to treat Alzheimer’s
BioWorld Science
Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...
Amlogenyx’s AM-805 reduces amyloid plaques in AD
BioWorld Science
The potent carboxypeptidase enzyme protective protein cathepsin A (PPCA) is known to cleave the C-terminus of amyloid-β42, responsible for aggregation and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 31, 2026
Atai Therapeutics patents new 5-HT2 receptor agonists
BioWorld Science
Atai Therapeutics Inc. has identified new 5-HT2 receptor agonists potentially useful for the treatment of psychiatric disorders.